Scientists compared ways of drug delivery to malignant tumors

April 08, 2019

A team of biologists from Sechenov First Moscow State Medical University and Lobachevsky University (Nizhny Novgorod) analyzed available methods of targeted drug delivery to malignant tumors. Individual approaches to cancer therapy limit the influence of drugs on healthy tissues and reduce side effects. The results of the study were published in the Cancers journal. The research was supported by a grant issued by the Ministry of Science and Higher Education .

The difference between healthy tissue and a tumor lies in the structure of its vasculature and changes in metabolism. In tumors blood vessels are formed chaotically, have different shapes and diameters, and exhibit closed ends and protrusions. The structure of lymphatic vessels also changes. A tumor and its vasculature grow at different speed causing oxygen and nutrients deficiency. The structure of the tissue and its metabolism changes, as well as the profile of molecules on the surface of tumor cells, and the cancer progresses. Taking these facts into consideration, one can develop methods of target antitumor drugs delivery without affecting healthy cells and causing unnecessary side effects.

Currently, there are three main ways of targeted drug-to-tumor delivery: passive targeting that takes into account the structure of the vessels; active targeting in which an antitumor drug binds with a molecular target; and cell-mediated targeting.

Due to the peculiarities of tumor vessels, large molecules can enter them relatively easily and accumulate in the tumor tissue. This phenomenon is known as enhanced permeability and retention effect, and passive drug targeting is based on it. However, this delivery method doesn't always guarantee a desired effect. To increase its efficiency, individual therapies are developed on the basis of tumor characteristics. For example, the size of an agent may be optimized accordingly.

Active targeting complements the passive method. It increases the accumulation of a drug in tumor and the time of its retention. In their earlier work the team presented a multifunctional complex that leads to a synergistic effect of combined chemo- and radiotherapy agents. The base of the complex is a luminescent nanoparticle that contains a radioactive isotope 90Y used in radionuclide therapy. On the surface there is a bound highly active fragment of exotoxin A obtained from Pseudomonas aeruginosa (PE40). The complex binds with a marker protein of cancer cells, and its toxic agents affect the tumor. This treatment method works because tumor cells have different metabolism and molecular profiles than the cells of healthy tissues.

Certain types of cells are able to penetrate tumor tissues and therefore can also be used to deliver drugs. Cell-mediated targeting extends the washout period, controls the release of the drug, and reduces general toxicity and side effects. This method has its limitations, but it is also very promising.

"Having a choice between various treatment methods that take into account molecular and structural characteristics of a tumor and being able to adjust drug administration regime means approaching the goals of personalized medicine," said Irina Balalayeva, a Candidate of Biological Sciences, Dean of the Department of Biophysics of the Institute of Biology and Biomedicine at Lobachevsky University, and a senior research associate of the laboratory of nanotheranostics at the Institute of Molecular Medicine, Sechenov Moscow State Medical University.

Understanding the processes of nutrients and metabolic products transportation within a tumor, the peculiarities of its structure, and its interaction with immune system cells can help increase the efficiency of antitumor drug delivery and cancer treatment.

Sechenov University

Related Tumor Cells Articles from Brightsurf:

A more sensitive way to detect circulating tumor cells
Breast cancer is the most frequently diagnosed cancer in women, and metastasis from the breast to other areas of the body is the leading cause of death in these patients.

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

How to prevent the spread of tumor cells via the lymph vessels
Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg identified a new way to block the dangerous spread of tumor cells via lymphatic vessels.

The CNIO reprograms CRISPR system in mice to eliminate tumor cells without affecting healthy cells
CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them.

Feeding off fusion or the immortalization of tumor cells
Despite all recent progress, cancer remains one of the deadliest human diseases.

How do tumor cells divide in the crowd?
Scientists led by Dr. Elisabeth Fischer-Friedrich, group leader at the Excellence Cluster Physics of Life (PoL) and the Biotechnology Center TU Dresden (BIOTEC) studied how cancer cells are able to divide in a crowded tumor tissue and connected it to the hallmark of cancer progression and metastasis, the epithelial-mesenchymal transition (EMT).

How tumor cells evade the immune defense
Scientists are increasingly trying to use the body's own immune system to fight cancer.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

New pathway to attack tumor cells identified
A study led by the Institut de Neurociències (INc-UAB) describes a new strategy to tackle cancer, based on inducing a potent stress in tumor causing cell destruction by autophagy.

Nutrient deficiency in tumor cells attracts cells that suppress the immune system
A study led by IDIBELL researchers and published this week in the American journal PNAS shows that, by depriving tumor cells of glucose, they release a large number of signaling molecules.

Read More: Tumor Cells News and Tumor Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to